alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS FINANCIAL INFORMATION EXTRACTED FROM THE AUDITED
CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 1999 AND THE AUDITED CONSOLIDATED
STATEMENT OF OPERATIONS FOR THE TWELVE MONTHS ENDED DECEMBER 31, 1999 TOGETHER
WITH ALL NOTES THERETO AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<EXCHANGE-RATE>                                      1
<CASH>                                         982,105
<SECURITIES>                                         0
<RECEIVABLES>                                7,026,217
<ALLOWANCES>                               (1,217,477)
<INVENTORY>                                  4,168,209
<CURRENT-ASSETS>                            13,511,169
<PP&E>                                      12,243,278
<DEPRECIATION>                             (3,380,856)
<TOTAL-ASSETS>                              26,431,493
<CURRENT-LIABILITIES>                       19,378,428
<BONDS>                                      1,340,527
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                     60,000
<COMMON>                                        30,776
<OTHER-SE>                                   3,759,866
<TOTAL-LIABILITY-AND-EQUITY>                26,431,493
<SALES>                                     30,652,555
<TOTAL-REVENUES>                            30,652,555
<CGS>                                       30,369,479
<TOTAL-COSTS>                                9,897,520
<OTHER-EXPENSES>                             4,011,452
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             819,800
<INCOME-PRETAX>                           (14,222,834)
<INCOME-TAX>                                    17,521
<INCOME-CONTINUING>                       (14,240,355)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                              (14,240,355)
<EPS-BASIC>                                     (1.09)
<EPS-DILUTED>                                   (1.09)


</TABLE>
Editorial Note on Part 25
Editorial Note: Nomenclature changes to part 25 appear at 88 FR 45065, July 14, 2023.

§ 25.51 Environmental assessments and findings of no significant impact. ( a ) Data and information that are protected from disclosure by 18 U.S.C. 1905 or 21 U.S.C. 331(j) or 360j(c) shall not be included in the portion of environmental documents that is made public. When such data and information are pertinent to the environmental review of a proposed action, an applicant or petitioner shall submit such data and information separately in a confidential section and shall summarize the confidential data and information in the EA to the extent possible.
( b ) FONSI's and EA's will be available to the public in accordance with 40 CFR 1506.6 as follows: ( 1 ) When the proposed action is the subject of a notice of proposed rulemaking or a notice of filing published in the Federal Register, the notice shall state that no EIS is necessary and that the FONSI and the EA are available for public inspection at FDA's Dockets Management Staff. If the responsible agency official is unable to complete environmental consideration of the proposed action before a notice of filing of a food or color additive petition is required to be published under the act, and if the subsequent environmental analysis leads to the conclusion that no EIS is necessary, the final regulation rather than the notice of filing shall state that no EIS is necessary and that the FONSI and the EA are available upon request and filed in FDA's Dockets Management Staff.
( 2 ) For actions for which notice is not published in the Federal Register, the FONSI and the EA shall be made available to the public upon request according to the procedures in 40 CFR 1506.6.
( 3 ) For a limited number of actions, the agency may make the FONSI and EA available for public review (including review by State and areawide information clearinghouses) for 30 days before the agency makes its final determination whether to prepare an EIS and before the action may begin, as described in 40 CFR 1501.4(e). This procedure will be followed when the proposed action is, or is closely similar to, one that normally requires an EIS or when the proposed action is one without precedent.
#### The State *v.*Winstandley et al.

[Nos. 18,687, 18,689, 18,690, 18,691, 18,692, 18,693, 18,694, 18,695, 18,700.

Filed April 17, 1900.]

From the Clark Circuit Court.

*Affirmed.*

*H. C. Montgomery, W. G. Ute, J. K. Marsh, W. L. Taylor,*Attorney-General, *Merrill Moores*and *O. G. Hadley,*for State.

*A. Dowling, C. L. Jewett, H. E. Jewett, M. Z. Stannard, W. H. Watson, C. D. Kelso*and *J. V. Kelso,*for appellees.

Baker, J.

The facts are the same as in *State*v. *Winstandley, ante,*443, except as to names and amounts. On the authority of that case, the judgment is affirmed.
[No. 20365-1-II.

Division Two.

December 5, 1997.]

#### The State of Washington, *Respondent,*v. George T. Tillett, *Appellant.*

Appeal from a judgment of the Superior Court for Kit-sap County, No. 95-1-00694-7, Jay B. Roof, J., entered February 9, 1996. *Affirmed*by unpublished opinion per Morgan, J., concurred in by Seinfeld and Armstrong, JJ.
§ 310.538 Drug products containing active ingredients offered over-the-counter (OTC) for use for ingrown toenail relief. ( a ) Any product that bears labeling claims such as for “temporary relief of discomfort from ingrown toenails,” or “ingrown toenail relief product,” or “ingrown toenail reliever,” or similar claims is considered an ingrown toenail relief drug product. Benzocaine, chlorobutanol, chloroxylenol, dibucaine, tannic acid, and urea have been present as ingredients in such products. There is lack of adequate data to establish general recognition of the safety and effectiveness of these or any other ingredients for OTC use for ingrown toenail relief. Based on evidence currently available, any OTC drug product containing ingredients offered for use for ingrown toenail relief cannot be generally recognized as safe and effective.
( b ) Any OTC drug product that is labeled, represented, or promoted for ingrown toenail relief is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved application or abbreviated application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved new drug application or abbreviated new drug application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any drug product labeled, represented, or promoted for OTC use for ingrown toenail relief is safe and effective for the purpose intended must comply with the requirements and procedures governing the use of investigational new drugs set forth in part 312 of this chapter.
( d ) After March 9, 1994, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
( e ) This section does not apply to sodium sulfide labeled, represented, or promoted for OTC topical use for ingrown toenail relief in accordance with part 358, subpart D of this chapter, after June 6, 2003.
[58 FR 47605, Sept. 9, 1993, as amended at 68 FR 24348, May 7, 2003]
Er. c11rrora B. cTonc5? 

Prooiaent ??lect 

Taxa ToohnologIoal c011cc0 

spur, TCsc?B 

Daor Sir: 

Oplnlon No, o-92 

Rsr L&@ity of.ounday Football Cams8 

You roymot an opinion of thle Departmnt In m8~oase \ 

to the yxstlon whothcr Toxcm Tsoh, balng D State lnatitutlon, 

10 prohibitma fro:: plajiinc a football @ma on Sunaq.w 

Your Gttontion is t?irootoa to Chapter :! of Tit10 7 of 

tho Penal Code of 3.mm, bcir..g Artiolos FX33 to 287, laOlu8I~ 

ontitlod WuncQq~ Laws". Thoao statute0 oet out In aetdl whd 

00t9 cre pr0hIbitoa on mneay, to.ather with nmerouD a?cooptlonEI 

to the prohibitions thoroln oonta !? ned.- . 

There in no qxoIf.~o stotutorJ provioion prohibitin&' 

the plnyin:; of football or other nlnilcr ~apso on 8undtIy* iC!l PA p:.~.rCe no:1zrmw, GO max. Cr. R. XC?, 131 S.W,,llOl, 32 L.R.A. 

8 ) llw Pt ~a5 hold that Astlole 199 of the Psnal 

Co&'thcr. in offooi (now Artiole fit36 of the penal COae) &I¬ 

prohibit the illo;fn;;: of a bmobnll (gum on &maw, for rhloh 811 

a@d,ooIOn fee ~23 oh.miW. 

In vie.7 of thn fom~ol~ a80iai0n al Miatutae, It la 

our opinion .t!intho ?laylc~ or a football @EI@ on Sunday is not 

pro!dbItoa by law. i'l0 Co not know of my OtatUtorg pXWh3lapl 

which viou1i: prohibit the playin:; of 0. football ga!nQ on wlnday 

by Texm Toohnolo~lonl Collo~s, by rcxmon of the taot that It Is 

0 Stcte Institusion. 

Cur lnvostl~~tlon has been llmlted to the general 8$at8 

, 
ti. CliSSord n. Jonee, Jcmuory 27, lQ@Si! ’ 

statutes, ana IYO havo not unaerteken to deternine the srieot; it 

any, which any orWm.nco OS the City OS Lubbook may have upon the 

quoatlon oubnlttea. 

-, 

* 

YOur6 very truly 

ATpOR17EyGEFIT3RhLOF!IBXhS 

Aaslatant
**Exhibit31.1**

CERTIFICATIONS

I, Keith Stentiford,certify that

1. I have reviewed thisquarterly report on Form 10-Q of Spescom Software Inc.;

2. Based on my knowledge,this quarterly report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, notmisleading with respect to the period covered by this quarterly report;

3. Based on my knowledge,the financial statements, and other financial information included in thisquarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;

4. The registrant’s othercertifying officer(s) and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have:

a) designed suchdisclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this quarterly report is being prepared;

b) evaluated theeffectiveness of the registrant’s disclosure controls and procedures andpresented in this quarterly report our conclusions about the effectiveness ofthe disclosure controls and procedures, as of the end of the period covered bythis quarterly report based on such evaluation; and

c) disclosed in thisquarterly report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

5. The registrant’s othercertifying officer(s) and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the registrant’s auditors andthe audit committee of the registrant’s board of directors (or personsperforming the equivalent functions):

a) all significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and reportfinancial information; and

b) any fraud, whether ornot material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting
| Dated:  August 14, 2006 |
|------------------------------|
|                         |
| /s/ Keith  Stentiford        |   |
| Keith Stentiford             |
|                         |
| Chief Executive  Officer     |

 

----
CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



     In  connection  with the  Quarterly  Report  of  Tonga  Capital  Corp  (the
"Company")  on Form 10-QSB for the period ending June 30, 2006 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"). I, Charles
T. Phillips,  President,  Chief Executive Officer and Chief Financial Officer of
the company,  certify,  pursuant to 18 USC Section 1350, as adopted  pursuant to
Section 906 of the  Sarbanes-Oxley Act of 2002, that to the best of my knowledge
and belief.

        (1)     The Report fully complies with the requirements of Section 13(a)
                or 15(d) of the Securities Exchange Act of 1934; and

        (2)     The information contained in the Report fairly presents, in all
                material respects, the financial condition and results of
                operations of the Company.




                                         /s/ Charles T. Phillips
                                         --------------------------------
                                         Charles T. Phillips, President
Dated: August 18, 2006
<PAGE> 1

Exhibit 99.02

CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Amerityre Corporation (the "Company")
on Form 10-KSB for the period ending June 30, 2002 as filed with the
Securities and Exchange Commission on this date (the "Report"), I, David K.
Griffiths, Principal Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.


/S/ David K. Griffiths
David K. Griffiths
Principal Financial Officer
September 30, 2002
§ 211.137 Expiration dating. ( a ) To assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use, it shall bear an expiration date determined by appropriate stability testing described in § 211.166.
( b ) Expiration dates shall be related to any storage conditions stated on the labeling, as determined by stability studies described in § 211.166.
( c ) If the drug product is to be reconstituted at the time of dispensing, its labeling shall bear expiration information for both the reconstituted and unreconstituted drug products.
( d ) Expiration dates shall appear on labeling in accordance with the requirements of § 201.17 of this chapter.
( e ) Homeopathic drug products shall be exempt from the requirements of this section.
( f ) Allergenic extracts that are labeled “No U.S. Standard of Potency” are exempt from the requirements of this section.
( g ) New drug products for investigational use are exempt from the requirements of this section, provided that they meet appropriate standards or specifications as demonstrated by stability studies during their use in clinical investigations. Where new drug products for investigational use are to be reconstituted at the time of dispensing, their labeling shall bear expiration information for the reconstituted drug product.
( h ) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this section shall not be enforced for human OTC drug products if their labeling does not bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability data.
[43 FR 45077, Sept. 29, 1978, as amended at 46 FR 56412, Nov. 17, 1981; 60 FR 4091, Jan. 20, 1995]
**Exhibit 32**

 

**CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Pursuantto 18 U.S.C. § 1350, as adopted pursuant to § 906 of theSarbanes-Oxley Act of 2002, the undersigned officers of Pace Medical, Inc.,a Massachusetts corporation (the “Company”) do hereby certify, to the best ofsuch officers’ knowledge and belief, that:

 

(1) TheQuarterly Report of the Company on Form 10-QSB for the period ending September 30,2005 as filed with the Securities and Exchange Commission on or about the datehereof (the “Report”) fully complies with the requirements of Section 13(a) or15(d) of the Securities Exchange Act of 1934; and

 

(2) Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 

 
|   | /s/ Steven E. Hanson                  |                   |
|--------|---------------------------------------|------------------------|
|   | Steven E. Hanson                      |
|   | President and Chief Executive Officer |
|   | Date:                                 | November 14, 2005 |   |
|   |                                  |
|   |                                  |
|   | /s/ Ralph E. Hanson                   |                   |
|   | Ralph E. Hanson                       |
|   | Treasurer                             |
|   | Date:                                 | November 14, 2005 |   |

 

----
Argued and submitted November 19,

reversed and remanded December 15, 1999

#### CHARLES M. KEENAN, *Appellant, v.*Joan PALMATEER, Superintendent, Oregon State Penitentiary, *Respondent.*

(94C-11097; CA A105276)

991 P2d 1107

Steven H. Gorham argued the cause and filed the brief for appellant.

Brendan C. Dunn, Assistant Attorney General, argued the cause for respondent. With him on the brief were Hardy Myers, Attorney General, and Michael D. Reynolds, Solicitor General.

Before De Muniz, Presiding Judge, and Haselton and Wollheim, Judges.

PER CURIAM

*425PER CURIAM

Plaintiff appeals from a judgment dismissing a writ of habeas corpus, ORS 34.680(1), for lack of jurisdiction because plaintiff had been transferred to a correctional institution outside of Marion County. That dismissal, as the state acknowledges on appeal, was erroneous. *See McGee v. Johnson,*161 Or App 384, 387, 984 P2d 341 (1999) (^Jurisdiction vested upon the issuance of the writ and cannot be divested merely upon a change in the physical location of a plaintiff.”).

Reversed and remanded.
§ 165.3 Definitions. ( a ) A *lot* is: ( 1 ) For purposes of determining quality factors related to manufacture, processing, or packing, a collection of primary containers or units of the same size, type, and style produced under conditions as nearly uniform as possible and usually designated by a common container code or marking, or in the absence of any common container code or marking, a day's production.
( 2 ) For purposes of determining quality factors related to distribution and storage, a collection of primary containers or units transported, stored, or held under conditions as nearly uniform as possible.
( b ) A *sample* consists of 10 subsamples (consumer units), one taken from each of 10 different randomly chosen shipping cases to be representative of a given lot, unless otherwise specified in a specific standard in this part.
( c ) An *analytical unit* is the portion(s) of food taken from a subsample of a sample for the purpose of analysis.
<PAGE>   1
               CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS


The Board of Directors
Spacelabs Medical, Inc.:


We consent to incorporation by reference in the registration statement (No.
333-15815) on Form S-8 of Spacelabs Medical, Inc. of our report dated June 11,
1999 relating to the statements of assets available for plan benefits of
Spacelabs Medical, Inc. Incentive Savings and Stock Ownership Plan as of
December 31, 1998 and 1997, and the statements of changes in assets available
for plan benefits for the years then ended and the related supplementary
schedules as of and for the year ended December 31, 1998, which report appears
in the December 31, 1998 annual report on Form 11-K of Spacelabs Medical, Inc.
Incentive Savings and Stock Ownership Plan.



KPMG LLP



Seattle, Washington
June 25, 1999
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Page 8975]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3922]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; Review of Minority Biomedical 
Research Support Chemistry Applications.
    Date: March 18-19, 2010.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency, Bethesda, MD 20814.
    Contact Person: John J. Laffan, PhD, Scientific Review Officer, 
Office of Scientific Review, National Institute of General Medical 
Sciences, National Institutes of Health,Natcher Building, Room 
3AN18J, Bethesda, MD 20892, 301-594-2773, <a href="/cdn-cgi/l/email-protection#cba7aaadadaaa5a1a48ba6aaa2a7e5a5a2a3e5aca4bd"><span class="__cf_email__" data-cfemail="761a17101017181c19361b171f1a58181f1e58111900">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives, National Institutes of Health, HHS)

    Dated: February 19, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-3922 Filed 2-25-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>